Zymeworks Inc. has obtained IND clearance from the FDA for ZW-171, a novel T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers. Clinical development will begin this year, and additional applications will be filed in the second half of the year seeking trial clearances in other territories.
The immune cell restricted guanine nucleotide exchange factor (GEF) and scaffolding protein VAV1 plays a key role in mediating T-cell receptor (TCR) and B-cell receptor (BCR) activity and signaling.
Inflammatory bowel disease (IBD) is sometimes associated with spondyloarthritis (SpA) and it highly impacts patients’ quality of life. It is crucial to understand the pro-inflammatory processes that take place during the pathogenesis of IBD-associated SpA.
Researchers from Lund University presented data from a study that aimed to identify novel targets for immunotherapy in acute myeloid leukemia (AML). To identify differentially expressed cell surface proteins in the primitive CD34+CD38- cell populations, an arrayed antibody screen was performed on primary bone marrow samples from patients with AML as well as healthy donors.
The first oral session in the acute myeloid leukemia (AML) translational research track of June 15, was given by Eliza Yankova, from the University of Cambridge, who presented collaborative studies done together with Storm Therapeutics Ltd. outlining pharmacological inhibition of METTL1 as a therapeutic strategy in AML treatment.
Samsara Therapeutics Inc. has described autophagy inducers reported to be useful for the treatment of amyotrophic lateral sclerosis and Parkinson’s disease.
Alterome Therapeutics Inc. has disclosed RAC-α serine/threonine-protein kinase (AKT1; PKBα) (E17K mutant) inhibitors reported to be useful for the treatment of cancer.
Enanta Pharmaceuticals Inc. has divulged macrocyclic chalcone-amide compounds acting as non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors.
RSS
